L oss of response (LOR) to anti-tumor necrosis factor (TNF) is frequent in patients with inflammatory bowel disease (IBD). 1, 2 In IFX-treated patients, the annual risk for LOR was calculated to be 13% per patient-year. 1 In adalimumab-treated patients, the annual risk of LOR was 24.4% par patient-year. 2 Predicting LOR to anti-TNF therapy remains a challenge in clinical practice.
Several noninvasive tools are used to monitor patients with IBD, including C-reactive protein (CRP), fecal calprotectin, and therapeutic drug monitoring of anti-TNF therapy. Two meta-analyses demonstrated that serum levels and antibodies to infliximab (IFX) and adalimumab are associated with LOR in IBD. 3, 4 A metaanalysis of fecal calprotectin for predicting relapse in patients with quiescent IBD disclosed ability to predict relapse with a pooled sensitivity and specificity of 78% and 73%, respectively. 5 The best way to predict LOR to anti-TNF therapy remains to be determined. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In a recent prospective and observational study of 93 patients in clinical remission after IFX induction therapy, elevated CRP levels, stable ATI above 20 ng/mL, and TLI below 5.5 mg/mL were predictive of subsequent LOR but no predictive model was developed. 13 In the Ultra 3 extension study on adalimumab, CRP levels and low albumin concentrations were identified as factors associated with LOR. 14 Limitations of available studies are their retrospective study design, 9 the analysis of predictive factors at the end of anti-TNF induction, 7, 8, 10, 13, 15 the analysis of only one biomarker, or of pharmacokinetics separately from biomarkers. [6] [7] [8] [9] [10] [11] [12] [14] [15] [16] [17] [18] No study aimed to develop the best Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
predictive model of LOR by including all biomarkers measured in routine practice together with pharmacokinetics of IFX in patients with IBD on sustained clinical remission. Hence, there was an urgent need to develop and validate models able to predict LOR in IFX-treated patients with Crohn's disease.
For that purpose, we conducted a prospective study to identify predictors of LOR in a well-defined cohort of patients with CD with a standardized follow-up. To develop and validate our model, we used training and test cohorts.
METHODS
A prospective single-center observational cohort study was conducted between January 2011 and June 2014. All consecutive adult patients with CD who were followed up at Saint Etienne University Hospital and in clinical remission under IFX maintenance therapy at a dose of 5 mg/kg every 8 weeks for at least 16 weeks were included. Patients were followed up for at least 9 months, and Crohn's Disease Activity Index (CDAI) disease activity score was calculated at every IFX infusion.
Clinical remission was defined by a CDAI ,150. LOR was defined by a CDAI .220 associated with fecal calprotectin .450 mg/g stools and resulting in a treatment change as judged by the physician (IFX optimization, change in IBD-related medications, and/or need for surgery).
Blood and fecal samples were taken from every included patient just before every IFX infusion for measuring CRP, trough levels of IFX (TLI), antibodies against IFX (ATI), and fecal calprotectin. Analysis was blinded to clinical and biological data.
Two thresholds of TLI therapeutic levels (.2 and 3 mg/mL) 4, [19] [20] [21] were consecutively assessed to identify the best model of LOR prediction. Stable ATI was defined by ATI .20 ng/mL for at least 2 consecutive times. 13 CRP levels ,5 mg/L were considered normal, and fecal calprotectin levels ,50 or ,250 mg/g of stools were consecutively used to identify the best biomarker of remission. 22, 23 All patients treated with another anti-TNF before IFX, needing IFX optimization before inclusion, and with perianal fistulizing CD were excluded from the analysis. Pregnant and patients ,18 years were also excluded. All patients signed a consent form. The protocol was approved by our local ethics committee and CNIL (1849323 v 0).
Measurement of IFX Trough Levels, ATI, and Fecal Calprotectin
Serum samples are routinely and systematically collected just before every IFX infusion and stored at 2208C. TLI and ATI concentrations were all measured using the Lisa-Tracker Premium Infliximab ELISA kit (Theradiag, France). This assay has been developed to reduce low-affinity binding of immune complexes or interfering molecules such as the rheumatoid factor. The use of specific buffers for both binding and washing steps allows a very efficient capture of free molecules. Fecal calprotectin was measured in stools using the Quantum Blue Calprotectin assay (Buhlmann, Switzerland).
Statistical Analysis
Statistical analysis was conducted using IBM SPSS statistical software, version 19 (IBM, Bois-Colombe, France). One-way statistical analysis was performed for each variable; the variable distribution comparisons were made using the chi-square test; Kaplan-Meier model was used to study the occurrence of relapses in time and the logistic model for measuring risk and build predictive rules. For that the approach we have adopted is supervised learning.
A predictive rule for the recognition of candidate patients to relapse is built from a random training sample extract of the study population. A multivariate model is used to select the relevant variables in predicting relapse. The combinations of values of selected variables that best predict relapse used to define the decision rule. This rule is then validated on the test sample, which consists of patients belonging to the study population and do not belong to the training sample. The sharing of the study population between learning sample and test sample is empirical; current sharing is 65%-35% or 70%-30%. 24 In order not to overestimate the learning capacity, we preferred sharing a 46%-54% and so privileged the validation of rules obtained.
RESULTS

Study Population
Among the 250 patients treated with IFX in our center, 119 patients met the inclusion criteria and were followed up for at least 9 months (median age of 35 yrs, median disease duration ¼ 7.4 yrs, treatment duration with IFX ¼ 12 mo, and median follow-up after inclusion ¼ 14 mo). Patient characteristics are reported in Table 1 .
At the inclusion, 28% and 35% of patients presented TLI ,2 and 3 mg/mL, respectively. Fifty-three percent and 25% of patients had a fecal calprotectin level above 50 and 250 mg/g stools, respectively. 
LOR During Follow-up
Characteristics of patients at the inclusion were comparable in the group of patients presenting LOR during follow-up (n ¼ 37) compared with patients without LOR (n ¼ 82). Patient characteristics of each subgroup according to LOR during follow-up are reported Table 1 .
During follow-up, 37 patients (31.1%) of the 119 relapsed after a mean period of 4.6 months, 78% within the first 6 months. IFX was intensified in 20 patients and a switch to adalimumab was decided in 12 patients, whereas surgery was required in 5 patients during follow-up.
Factors Associated with LOR
The results of bivariates analysis are presented in Table 2 . Kaplan-Meier models show the dynamics of relapse occurred for stable ATI at inclusion (Fig. 1A) , TLI at inclusion ,2 mg/mL (Fig. 1B) , CRP at inclusion .5 mg/L ( Fig. 2A) , and fecal calprotectin levels at inclusion .250 mg/g stools (Fig. 2B) .Conversely, TLI ,3 mg/mL (P ¼ 0.6), fecal calprotectin .50 mg/g stools (P ¼ 0.1), and immunosuppressive therapy (P ¼ 0.5) at inclusion were not predictive of LOR during the follow-up (Table 2) .
We next performed a stepwise logistic modeling including four parameters: CRP, TLI, stable ATI, and fecal calprotectin (Table 3) . Only results for fecal calprotectin levels .250 mg/g stools (OR: 4.09; 95% CI, 1.01-16.21; P ¼ 0.049) and TLI ,2 mg/mL (OR: 14.85; 95% CI, 3.67-60; P ¼ 0.000) were statistically significant. A Kaplan-Meier curve shows the dynamics of relapse (Fig. 3) .
Predictive Model for LOR
A training cohort of 55 patients was isolated randomly to implement a predictive model for LOR (Tables 4 and 5 ). The combination of calprotectin .250 mg/g stools and TLI ,2 mg/ mL predicted LOR in 78.3% of the cases within 6 months. Conversely, calprotectin .250 mg/g stools alone predicted significantly lower LOR (sensitivity ¼ 0.37, specificity ¼ 0.82, PPV ¼ 0.63, and NPV ¼ 0.75). Similarly, TLI ,2 mg/mL alone predicted significantly lower LOR (sensitivity ¼ 0.53, specificity ¼ 0.80, PPV ¼ 0.65, NPV ¼ 0.78).
We performed logistic models for LOR including biomarkers of inflammation (CRP and fecal calprotectin levels at inclusion) and/or TLI ( Table 4 ). The most accurate predictive rules to predict LOR during follow-up associated with TLI were ([TLI #2 mg/mL] and faecal calprotectin [$250 mg/g of stools]); we validated these rules on the test cohort of 64 different patients. Our predictive rules enabled to predict LOR in this test cohort in an accuracy of 87% of the cases within 6 months, (sensitivity ¼ 0.94, specificity ¼ 0.84, PPV ¼ 0.73, and NPV ¼ 0.97). The accuracy was lower using TLI ,2 mg/mL and calprotectin .50 mg/g stools (82%), TLI ,3 mg/mL and calprotectin .250 mg/g stools (76%), or TLI ,3 mg/mL and calprotectin .50 mg/g stools (80%) ( Table 4) .
The accuracy was lower using TLI ,2 mg/mL and CRP .5 mg/L (77%). Conversely, a combination of calprotectin .250 mg/g stools and CRP .5 mg/L enabled to predict LOR with PPV, NPV of 70% and 73%, respectively and accuracy of 74%. Finally, accuracy of the model was not improved using CRP, calprotectin, and TLI in our predictive model (Table 5 ). 
DISCUSSION
LOR is frequent in patients with CD under IFX and is estimated at 13% annually. 1 It is therefore essential to be able to predict this secondary LOR with noninvasive monitoring tools. The purpose of our work was to define a predictive score for LOR to isolate as soon as possible the group of patients requiring treatment optimization. We demonstrated in a univariate analysis that 4 factors are associated to patients with CD in clinical remission for at least 16 weeks in the absence of relapse. A normal CRP level has been reported in a cohort study to be associated with a favorable clinical outcome under IFX. The authors reported that early normalization of CRP levels correlated with sustained longterm response (P , 0.001). 25 Fecal calprotectin in a recent metaanalysis was also associated to clinical relapse in patients with CD, 5 but the authors had not been able to isolate predictive thresholds associated to relapse because of the great heterogeneity of fecal calprotectin measurement. Calprotectin levels increase in the 6 months preceding the LOR. 26 In our study, we have used the previously described threshold associated with mucosal healing (250 mg/g stools), 22 and have compared its performances for LOR prediction with those of other known thresholds. 23 Fecal calprotectin is one of the two parameters isolated by our Cox model. Other calprotectin thresholds were also tested in our study (notably 50 mg/g) as they may be more strongly associated with mucosal healing 27,28 but unfortunately was not predictive in our model with LOR during the follow-up. This threshold was not accurate enough for predicting clinical relapse but conversely for predicting sustained clinical and mucosal healing remission. In a post hoc analysis of STORI trial, 26 in multivariate analysis, serum calprotectin (threshold: 5675 ng/mL) seemed complementary to CRP (.5 mg/L) and fecal calprotectin (.250 mg/g) to predict relapse after IFX withdrawal (P ¼ 0.0173, 0.0024 and 0.0002; OR: 3.191, 3.561, and 4.120). 26 However, fecal calprotectin levels .250 mg/g alone were not sufficient to predict relapse with a very low sensitivity (0.37) and lower PPV and NPV compared with the combination use of fecal calprotectin levels and TLI. In our study, CRP levels seemed not complementary to fecal calprotectin to predict relapse. The use of pharmacokinetics of anti-TNF showed a high correlation between residual IFX trough levels, stable antibodies, and clinical/endoscopic response. 13 We showed in our study in both bivariate analysis and in the logistic model that IFX trough levels ,2 mg/mL were associated with LOR. However, TLI alone ,2 mg/mL was not sufficient to predict relapse with a very low sensitivity (0.53) and lower PPV and NPV compared with fecal calprotectin levels and TLI. In CD, it has been reported that TLI levels .3 mg/mL at week 14 were predictive of a deep and sustained clinical response. 19, 20 Using our enzyme-linked immunosorbent assay test, we have previously identified a TLI threshold of 2 mg/mL. 4 We have found that a TLI level ,3 mg/mL was not predictive of LOR in univariate analysis in our study. In univariate analysis, stable ATIs as reported previously were predictive of LOR. 13 In our study using the logistic model, this parameter disappeared but if TLI is not included in the model, ATIs are clearly associated with LOR, thus indicating that the predictive value of ATI is dependent on TLI. Although most recent studies detected significantly lower incidence of ATI among patients who were concomitantly treated with immunomodulators, few reported that concurrent immunomodulators have no effect on the rate of ATI formation. 24, [28] [29] [30] [31] In a recent study, combination therapy resulted in significantly longer ATI-free survival compared with monotherapy. 15 Furthermore and similar to the findings of the SONIC trial, combination therapy also significantly prolonged survival free of LOR even in the scheduledtherapy patients (see Fig. Supplemental Digital Content 1, http:// links.lww.com/IBD/B407). 29 If concomitant immunosuppressors treatment did not influence LOR, the results reported in our study could be explained by the fact that more than 90% of the patients included were on combotherapy for at least 6 months when starting IFX. Thus, the proposed score based on calprotectin and TLI is highly predictive of LOR in more than 85% of cases in the short term. We have validated this score by randomizing an independent cohort, further strengthening our results. Some studies have reported a predictive value to sustained clinical remission using TLI and CRP levels. In a post hoc analysis of the ACCENT 1 trial, patients with durable sustained response to maintenance IFX 5 mg/kg had higher postinduction trough levels than patients without durable response. 7 Serum IFX trough levels $3.5 mg/mL and a $60% CRP decrease were significantly associated with durable response. 7 Moreover, TLI at week 30 of 3.0 mg/mL or greater (OR, 3.34; 95% CI, 1.53-7.28) and CRP normalization (OR, 2.69; 95% CI, 1.10-6.54) were associated with mucosal healing at week 26. 32 A combination of CRP .5 mg/L and TLI ,2 mg/mL predicted LOR in our study with an accuracy of 77%. A measurement of IFX trough levels is not available for every physician; we also looked at a new model not incorporating pharmacokinetics of IFX. Models using CRP and fecal calprotectin levels were less accurate (74%) to predict LOR, confirming the clinical utility of TLI to predict LOR. Despite the cost of some tests, mainly the TLI, the early detection of the LOR group would certainly allow a better control of the disease and possibly reduce the overall cost.
This study has several strengths: it is a large prospective cohort of patients, biological data were analyzed blindly, and we validated our model in an independent cohort. We have considered several known thresholds of TLI (2 and 3 mg/mL) and fecal calprotectin (50 and 250 mg/g stools) and have kept the best of each one for the LOR prediction model. We did not use in our model endoscopic scoring systems.
In patients in clinical remission under IFX, our score (TLI #2 mg/mL and fecal calprotectin [$250 mg/g of stools]) predicted a short-term clinical relapse with a high accuracy of 87%, thus identifying a subgroup of patients requiring therapeutic optimization. In the subgroup of patients, calprotectin seems to be a biomarker of inflammation in the tissue and low TLI as the explanation of why patients relapse. But, to date, we still do not know which the first step is. In some patients, TLI could decrease before the increase of calprotectin level. Conversely, in some patients, calprotectin could increase before the decrease of TLI. Our data need to be validated in an independent multicenter study. Moreover, our results highlight the clinical utility of IFX trough levels to predict LOR. Indeed, half of our patients with low TLI (,2 mg/mL) without increase in fecal calprotectin did not present LOR during follow-up. Hence, it is not necessary to increase the dose of IFX in this subgroup of patients. A low TLI ranging from 2 to 3 mg/mL is not sufficient to predict LOR and should not lead to optimization of IFX use. Hence, similar to a recent meta-analysis, our study suggests that the best threshold of TLI for the prediction of LOR is 2 mg/mL. These results could explain, at least in part, the negative results of the primary endpoint from TAXIT trial. 21 
